A recently published study examined whether HPV genotype influences the severity of recurrent respiratory papillomatosis (RRP) in children. Researchers found that children with HPV-11 experienced significantly more aggressive disease, requiring more surgeries and demonstrating higher disease severity scores than those with HPV-6.

A groundbreaking study from South Africa explored the use of Gardasil® as an adjunctive therapy for juvenile-onset recurrent respiratory papillomatosis (JoRRP). Researchers observed substantial reductions in disease severity, longer intervals between surgeries, and lower tracheostomy rates, offering new evidence supporting the potential role of HPV vaccination in established RRP cases.

A new study comparing patient experiences with surgery and systemic bevacizumab found that 83% of patients preferred bevacizumab and reported better voice, breathing, less pain, and improved mental health. Here's what the research found.

A newly published study in The Laryngoscope draws on data from the RRPF/CoRDS Patient Registry to quantify what our community has long known: RRP impacts far more than the airway. Here's what the research found.